Antenatal Care
Gothenburg, Sweden
NCT Number: NCT05329428
Vitamin D deficiency is common among certain risk groups in Sweden, and occurs approximately in every tenth pregnant woman.The aim of the randomized double-blind controlled trial Pregnancy vitamin D intervention (PREDIN) is to investigate the dose of vitamin D supplementation required in achieving vitamin D sufficiency (25OHD ≥50 nmol/l) in pregnant women at risk of vitamin D deficiency. In addition, the investigators aim to examine if the overall vitamin D status and vitamin D intake have increased since the expanded vitamin D fortification program was initiated in year 2020.
Looking for future studies?
Notify Me18 year–45 year
Female
Interventional
Not applicable
Gothenburg, Sweden
The effect of maternal vitamin D in pregnancy for maternal and offspring health needs to be clarified. In observational studies, the investigators and others show associations between poor maternal vitamin D status in pregnancy and an increased risk of pregnancy complications. Poor maternal vitamin D status is also linked to impaired growth in the first year of life, and potentially also to higher risk of developing obesity in childhood. Risk factors for vitamin D deficiency in Swedish pregnant women are related to lower intake of vitamin D and to less sun exposure.
Since the evidence for positive effects of maternal vitamin D status or intake is limited, vitamin D interventions in pregnancy are warranted to clarify the causal effects of vitamin D in pregnancy and the doses required to achieve sufficient vitamin D status in deficient women. In the first trimester, pregnant women will be screened at a routine visit in the antenatal care for the risk of vitamin D deficiency using a validated questionnaire. Women who are classified as having a high risk of vitamin D deficiency will be randomized to one of three study arms: usual antenatal care, 20 µg vitamin D per day or 40 µg vitamin D per day. The participants will be followed up until delivery. Blood will be collected for analysis of vitamin D status (25OHD) at screening and in the third trimester of pregnancy. Information regarding pregnancy, gestational complication and fetal growth will be retrieved from medical records after delivery. About 500 women will be screened and their vitamin D status and vitamin D intake will be compared to a previous population-based cohort study, to investigate if the status or intake of vitamin D has increased since the expanded food fortification program was introduced.
The study hypothesis is that vitamin D status and/or vitamin D intake is related to risk of developing complications during pregnancy or delivery and that maternal supplementation with vitamin D during pregnancy will be effective in achieving vitamin D sufficiency in pregnant women at risk of vitamin D deficiency. In addition, the investigators hypothesize that the expanded vitamin D food fortification program has increased the vitamin D status and vitamin D intake of pregnant women in Gothenburg since 2013-2014.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
At a routine visit at the antenatal care in early pregnancy (gestational week <15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 20 µg (800 IE), are taken daily throughout pregnancy.
At a routine visit at the antenatal care in early pregnancy (gestational week <15) women will be provided with with vitamin D3 (cholecalciferol) supplements. Two tablets, with a total content of 40 µg (1600 IE), are taken daily throughout pregnancy.
In early pregnancy (gestational week <15) women are advised by the regular midwife to take a daily supplement of Vitamin D throughout pregnancy, according to usual antenatal care routines.
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Analyses of 25OHD (25OHD3 and 25OHD2) from blood samples drawn in first- and third trimester of pregnancy
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Analyses of 25OHD (25OHD3 and 25OHD2) from blood samples drawn in first- and third trimester of pregnancy
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Analyses of vitamin D metabolites 3-epi-25-Hydroxyvitamin D3 from blood samples drawn in first- and third trimester of pregnancy
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Analyses of 1,25-dihydroxyvitamin D from blood samples drawn in first- and third trimester of pregnancy
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Analyses of vitamin D binding proteins from blood samples drawn in first- and third trimester of pregnancy
Time frame: At inclusion in first trimester of pregnancy
Analyses of gene variants in blood sample drawn at inclusion in first trimester of pregnancy
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Analyses of ferritin
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Analyses of hemoglobin
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Analyses of metabolomics in blood
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Analyses of inflammation e.g. c-reactive protein
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Analyses of inflammation e.g. interleukines
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Analyses of inflammation e.g. cytokines
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Analyses of cortisol
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Analysis of parathyroid hormone in sampled blood at the routine laboratory
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Analyses of estrogen, in sampled blood, at the routine laboratory
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Analyses of progesterone, in sampled blood, at the routine laboratory
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Analyses of 24,25(OH)2D (24,25(OH)2D3 and 24,25(OH)2D2)
Time frame: At inclusion in first trimester and at follow-up in third trimester, up to 9 months
Dietary intake of mother during pregnancy assessed by dietary record at two time points
Time frame: From inclusion in first trimester to follow-up in third trimester, up to 9 months
Self-reported weight (in kilograms) during pregnancy until delivery.
Time frame: Up to delivery
Diagnosis of pregnancy-induced hypertension
Time frame: Up to delivery
Diagnosis of pre-eclampsia
Time frame: Up to delivery (up to 9 months)
Diagnosis of gestational diabetes
Time frame: Up to 37 completed weeks
Delivery before 37 weeks completed weeks of gestation
Time frame: At delivery
SGA born infant
Time frame: At delivery
LGA born infant
Time frame: At delivery
IUGR
Time frame: At 1, 5 and 10 minutes after delivery
Vitality signs are estimated as Apgar scores at 1, 5 and 10 minutes after birth of the newborn. Apgar stands for Appearance, pulse, grimace, activity and respiration. The maximium score at each time point is 10 scores and a high score indicates high vitality, where as a low score indicates very low vitality.
Time frame: At delivery
Delivery by caesarean sections
Time frame: During the first 21+6 weeks of pregnancy
Miscarriage
Time frame: Any time during pregnancy after pregnancy week 22+0 (up to 9 months)
IUFD
Göteborg University
Other
PREDIN: Pregnancy and Vitamin D Intervention Study - A Randomized Controlled Trial
Acronym: PREDIN
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03330301
Arthritis, Asthma
Frederiksberg, Denmark
View Trial DetailsNCT03890458
Avitaminosis, Deficiency Diseases
Antalya, Turkey (Türkiye)
View Trial DetailsNCT07631312
Anemia, Anemia, Hypochromic
Atlanta, Georgia, United States
View Trial DetailsNCT06700122
Avitaminosis, Deficiency Diseases
Cairo, Egypt
View Trial Details